Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis

Código QR

Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis

Guardado en:

Detalles Bibliográficos
Autores principales:	Alice Tzeng, Tony H Tzeng, Moshe C Ornstein
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/dae64e52781b44a2a1ebf06a7cb4e9d9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Xiuqiong Chen, et al.
Publicado: (2021)

Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab
por: Tian Zhang, et al.
Publicado: (2021)

Progression‐free survival assessed per immune‐related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune‐checkpoint inhibitors in lung cancer: A systematic review and meta‐analysis
por: Guang‐Li Zhu, et al.
Publicado: (2021)

Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma
por: Yeon Jeong Kim, et al.
Publicado: (2021)

Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study
por: Xiaozhun Huang, et al.
Publicado: (2021)

Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Shinsuke Suzuki, et al.
Publicado: (2021)

Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review
por: María Rodríguez Plá, et al.
Publicado: (2021)

PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma
por: Xian-De Liu, et al.
Publicado: (2020)

Sarcopenia’s Prognostic Impact on Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Donggun Lee, et al.
Publicado: (2021)

Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors
por: Nicola Personeni, et al.
Publicado: (2021)

Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma
por: Gianluca Ianiro, et al.
Publicado: (2020)

Determinants of renal cell carcinoma invasion and metastatic competence
por: Kangsan Kim, et al.
Publicado: (2021)

Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma
por: Yang Liu, et al.
Publicado: (2021)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Di Wang, et al.
Publicado: (2021)

Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma
por: Marc-Oliver Grimm, et al.
Publicado: (2021)

Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis
por: Yuanfang Xin, et al.
Publicado: (2021)

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
por: Wolfram Samlowski, et al.
Publicado: (2021)

Treatment of Cutaneous Squamous Cell Carcinoma with Immune Checkpoint Inhibitors in Special Populations
por: Paolo Bossi, et al.
Publicado: (2021)

A methylomics-correlated nomogram predicts the recurrence free survival risk of kidney renal clear cell carcinoma
por: Xiuxian Zhu, et al.
Publicado: (2021)

Tuberculosis reactivation at ileum following immune checkpoint inhibition with pembrolizumab for metastatic nasopharyngeal carcinoma: a case report
por: Kin-Sang Lau, et al.
Publicado: (2021)

The Effect of Cytoreductive Partial Nephrectomy in Elderly Patients with Metastatic Renal Cell Carcinoma
por: Chen J, et al.
Publicado: (2020)

Metastatic renal cell carcinoma of unknown primary site. Clinical follow-up
por: N. A. Ognerubov, et al.
Publicado: (2020)

Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma
por: Matthew T. Campbell, et al.
Publicado: (2021)

The effect of antioxidant status on overall survival in renal cell carcinoma
por: Ivan Pavlović, et al.
Publicado: (2019)

Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
por: Pramod Savarapu, et al.
Publicado: (2021)

A three-feature prediction model for metastasis-free survival after surgery of localized clear cell renal cell carcinoma
por: Kalle E. Mattila, et al.
Publicado: (2021)

Indicators of responsiveness to immune checkpoint inhibitors
por: Bradley D. Shields, et al.
Publicado: (2017)

The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
por: Ethan Emberley, et al.
Publicado: (2021)

The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma
por: Ethan Emberley, et al.
Publicado: (2021)

Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade
por: Chisato Ohe, et al.
Publicado: (2021)

Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival
por: Fiamma Berner, et al.
Publicado: (2021)

Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [<sup>18</sup>F]FDG PET/CT in Metastatic Melanomas and Lung Cancer
por: Egesta Lopci
Publicado: (2021)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
por: Whitney E. Lewis, PharmD, et al.
Publicado: (2021)

The role of surgery on primary site in metastatic upper urinary tract urothelial carcinoma and a nomogram for predicting the survival of patients with metastatic upper urinary tract urothelial carcinoma
por: Xiaodi Zhang, et al.
Publicado: (2021)

Hypercalcemia following discontinuation of denosumab therapy: A systematic review
por: Keisuke Horiuchi, et al.
Publicado: (2021)

Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma
por: Kennedy Yao Yi Ng, et al.
Publicado: (2021)

Discontinuation of oral anticoagulation therapy after successful atrial fibrillation ablation: A systematic review and meta-analysis of prospective studies.
por: Xue-Hui Liu, et al.
Publicado: (2021)

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
por: Jeffrey J. Wallin, et al.
Publicado: (2016)

Gut Microbiota and Sunitinib-Induced Diarrhea in Metastatic Renal Cell Carcinoma: A Pilot Study
por: Su Z, et al.
Publicado: (2021)

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2– metastatic breast cancer
por: Forsythe A, et al.
Publicado: (2018)